S448 The Impact of Heart Failure on Colorectal Cancer Survival: A Propensity-Matched Cohort and Survival Analysis

Le résumé fourni par la source

Introduction: Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and accounts for a significant proportion of global cancer mortality. While advances in diagnosis and treatment have improved survival rates, CRC survivors face a substantial risk of non-cancer mortality, with cardiovascular disease (CVD) being a leading cause. Despite this, postoperative surveillance in CRC patients remains predominantly focused on cancer recurrence, often overlooking the significant burden of CVD. Emerging evidence suggests a complex interplay between CRC and CVD, driven by shared risk factors, chronic inflammation, and systemic treatment-related cardiotoxicity. Methods: A retrospective cohort analysis was conducted using data from the TriNetX federated network, comparing 2 groups: Cohort 1 included 360,005 adult patients (≥18 years) diagnosed with CRC (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM]: C18) without a diagnosis of heart failure (ICD-10CM: I50), while Cohort 2 consisted of 59,961 patients with both CRC and HF diagnosis. Propensity score matching was performed on 24 characteristics, including demographic variables (e.g., age, sex, race/ethnicity), oncology stage, and comorbid conditions (e.g., ischemic heart disease, diabetes mellitus, hypertensive diseases, chronic kidney disease). Cardiovascular outcomes between the cohorts were compared using risk measures and Kaplan-Meier survival analysis. Statistical significance was evaluated using the log-rank test and hazard ratios, and proportionality assumptions were tested. Results: Each cohort consisted of 45,731 matched patients. Among patients with CRC; HF cohort had significantly lower survival probabilities and higher mortality risk compared to cohort without HF. The outcome (death) in the control group was 30.3% and in the HF cohort group was 42.1%. We found that the odds ratio for mortality was 1.389 (P-value < 0.001) (confidence interval [CI] of 1.36-1.41). The hazard ratio (HR) for survival was 0.653 (95% CI: 0.639–0.667), indicating that the risk of death was substantially higher in CRC patients with HF. Median survival was reduced by over 1,200 days in the HF cohort. Conclusion: Current CRC surveillance predominantly focuses on cancer recurrence, often overlooking the risks posed by comorbid conditions like HF. The data presented compellingly advocate for a paradigm shift towards integrated care pathways that concurrently address the dual burden of cancer and cardiovascular disease, ultimately optimizing outcomes for CRC patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.